Cargando…
Engineering of Human Corneal Endothelial Cells In Vitro
Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfuncti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535652/ https://www.ncbi.nlm.nih.gov/pubmed/31171901 http://dx.doi.org/10.7150/ijms.30759 |
_version_ | 1783421594797867008 |
---|---|
author | Zhu, Qin Zhu, Yingting Tighe, Sean Liu, Yongsong Hu, Min |
author_facet | Zhu, Qin Zhu, Yingting Tighe, Sean Liu, Yongsong Hu, Min |
author_sort | Zhu, Qin |
collection | PubMed |
description | Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfunction is via corneal transplantation of a cadaver donor cornea with healthy corneal endothelium. Due to severe shortage of donor corneas worldwide, it has become paramount to develop human corneal endothelial grafts in vitro that can subsequently be transplanted in humans. Recently, we have reported effective expansion of human corneal endothelial cells by reprogramming the cells into progenitor status through use of p120-Kaiso siRNA knockdown. This new reprogramming approach circumvents the need of using induced pluripotent stem cells or embryonic stem cells. Successful promotion of this technology will encourage scientists to re-think how "contact inhibition" can safely be perturbed to our benefit, i.e., effective engineering of an in vivo-like tissue while successful maintaining the normal phenotype. In this review, we present current advances in reprogramming corneal endothelial cells in vitro, detail the methods to successful engineer human corneal endothelial grafts, and discuss their future clinical applications to cure corneal blindness. |
format | Online Article Text |
id | pubmed-6535652 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-65356522019-06-06 Engineering of Human Corneal Endothelial Cells In Vitro Zhu, Qin Zhu, Yingting Tighe, Sean Liu, Yongsong Hu, Min Int J Med Sci Review Human corneal endothelial cells are responsible for controlling corneal transparency, however they are notorious for their limited proliferative capability. Thus, damage to these cells may cause irreversible blindness. Currently, the only way to cure blindness caused by corneal endothelial dysfunction is via corneal transplantation of a cadaver donor cornea with healthy corneal endothelium. Due to severe shortage of donor corneas worldwide, it has become paramount to develop human corneal endothelial grafts in vitro that can subsequently be transplanted in humans. Recently, we have reported effective expansion of human corneal endothelial cells by reprogramming the cells into progenitor status through use of p120-Kaiso siRNA knockdown. This new reprogramming approach circumvents the need of using induced pluripotent stem cells or embryonic stem cells. Successful promotion of this technology will encourage scientists to re-think how "contact inhibition" can safely be perturbed to our benefit, i.e., effective engineering of an in vivo-like tissue while successful maintaining the normal phenotype. In this review, we present current advances in reprogramming corneal endothelial cells in vitro, detail the methods to successful engineer human corneal endothelial grafts, and discuss their future clinical applications to cure corneal blindness. Ivyspring International Publisher 2019-03-10 /pmc/articles/PMC6535652/ /pubmed/31171901 http://dx.doi.org/10.7150/ijms.30759 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Zhu, Qin Zhu, Yingting Tighe, Sean Liu, Yongsong Hu, Min Engineering of Human Corneal Endothelial Cells In Vitro |
title | Engineering of Human Corneal Endothelial Cells In Vitro |
title_full | Engineering of Human Corneal Endothelial Cells In Vitro |
title_fullStr | Engineering of Human Corneal Endothelial Cells In Vitro |
title_full_unstemmed | Engineering of Human Corneal Endothelial Cells In Vitro |
title_short | Engineering of Human Corneal Endothelial Cells In Vitro |
title_sort | engineering of human corneal endothelial cells in vitro |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535652/ https://www.ncbi.nlm.nih.gov/pubmed/31171901 http://dx.doi.org/10.7150/ijms.30759 |
work_keys_str_mv | AT zhuqin engineeringofhumancornealendothelialcellsinvitro AT zhuyingting engineeringofhumancornealendothelialcellsinvitro AT tighesean engineeringofhumancornealendothelialcellsinvitro AT liuyongsong engineeringofhumancornealendothelialcellsinvitro AT humin engineeringofhumancornealendothelialcellsinvitro |